US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Array Digital Infrastructure Inc.

38.03

-0.2500-0.65%

Post-market: 38.030.00000.00%16:51 EDT

Volume:235.03K

Turnover:8.95M

Market Cap:3.29B

PE:6.15

High:38.49

Open:38.49

Low:37.86

Close:38.28

52wk High:60.82

52wk Low:33.71

Shares:86.38M

Float Shares:15.56M

Volume Ratio:0.91

T/O Rate:1.51%

Dividend:- -

Dividend Rate:- -

EPS(TTM):6.19

EPS(LYR):0.5551

ROE:22.68%

ROA:0.02%

PB:2.60

PE(LYR):68.52

Loading ...

Overview Company News Filings

Voyager Reports First Quarter 2026 Financial and Operating Results

Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

Array Digital Infrastructure Inc expected to post earnings of $1.14 a share - Earnings Preview

BlockchAIn Digital Infrastructure to present at LD Micro Invitational Conference

Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026

Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026

Array Digital Infrastructure to report quarterly results, host webcast conference call

INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th

Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

Blockchain Digital Infrastructure announces annual shareholder meeting

Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis

Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio

A New "Dark Horse" Ingredient Emerges in the Sensitive Skin Market

Array Digital Infrastructure Inc expected to post earnings of 86 cents a share - Earnings Preview

InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability

CMS (867.HK; 8A8.SG): NDA for the Seasonal Allergic Rhinitis Indication of Class 1 Innovative Drug MG-K10 Accepted in China

Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”

Did Proposed Officer Liability Shield Just Shift Array Digital Infrastructure's (AD) Investment Narrative?

Simply Wall St.

Lynk Pharmaceuticals Announces NDA Acceptance for Zemprocitinib by NMPA

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/AD/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AD\",,,,,undefined,":{"symbol":"AD","market":"US","secType":"STK","nameCN":"Array Digital Infrastructure Inc.","latestPrice":38.03,"timestamp":1789502400000,"preClose":38.28,"halted":0,"volume":235030,"hourTrading":{"tag":"盘后","latestPrice":38.03,"preClose":38.03,"latestTime":"16:51 EDT","volume":12074,"amount":459174.22000000003,"timestamp":1789505510915,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.006530825496342737,"floatShares":15563300,"shares":86379877,"eps":6.185934,"marketStatus":"Post-Mkt","change":-0.25,"latestTime":"09-15 19:06:29 EDT","open":38.49,"high":38.49,"low":37.86,"amount":8946170.87359,"amplitude":0.016458,"askPrice":38.77,"askSize":51,"bidPrice":34.39,"bidSize":100,"shortable":3,"etf":0,"ttmEps":6.185934,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789516800000},"marketStatusCode":4,"adr":0,"exchange":"NYSE","adjPreClose":38.28,"postHourTrading":{"tag":"盘后","latestPrice":38.03,"preClose":38.03,"latestTime":"16:51 EDT","volume":12074,"amount":459174.22000000003,"timestamp":1789505510915,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.912179,"impliedVol":0.3544,"impliedVolPercentile":0.64},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AD\",,,,,undefined,":{"symbol":"AD","floatShares":15563300,"roa":"0.02%","roe":"22.68%","lyrEps":0.555055,"volumeRatio":0.912179,"shares":86379877,"dividePrice":0,"high":38.49,"amplitude":0.016458,"preClose":38.28,"low":37.86,"week52Low":33.71,"pbRate":"2.60","psRate":"15.38","week52High":60.82,"institutionHeld":0.3358,"latestPrice":38.03,"committee":0.324503,"eps":6.185934,"divideRate":0,"volume":235030,"delay":0,"ttmEps":6.185934,"open":38.49,"prevYearClose":53.62,"prevWeekClose":38.12,"prevMonthClose":36.66,"prevQuarterClose":36.26,"fiveDayClose":38.46,"twentyDayClose":35.36,"sixtyDayClose":38.86,"dividendPayoutRate":40.52599213795753,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0.4274298457535774},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"AD","fiscalQuarterEnding":"2026/06","expectedEps":0.27,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":0.44},{"date":"2026-06-11","symbol":"AD","amount":11,"announcedDate":"2026-06-01","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-11","defaultRemindTime":1781184600000,"name":"Array Digital Infrastructure Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-25","payableDate":"2026-06-11","currency":"USD","dateTimestamp":1781150400000,"payDate":"2026-06-25"},{"market":"US","date":"2026-05-08","symbol":"AD","fiscalQuarterEnding":"2026/03","expectedEps":-0.06,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":0.42},{"market":"US","date":"2026-02-20","symbol":"AD","fiscalQuarterEnding":"2025/12","expectedEps":0.32,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1771563600000,"reportTimeType":"pre","actualEps":0.48},{"date":"2026-01-23","symbol":"AD","amount":10.25,"announcedDate":"2026-01-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-23","defaultRemindTime":1769178600000,"name":"Array Digital Infrastructure Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-02","payableDate":"2026-01-23","currency":"USD","dateTimestamp":1769144400000,"payDate":"2026-02-02"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AD\",market:\"US\",,,undefined,":[{"executeDate":"2025-08-20","recordDate":"2025-08-11","paymentDate":"2025-08-19","value":23,"currency":"USD"},{"executeDate":"2026-01-23","recordDate":"2026-01-23","paymentDate":"2026-02-02","value":10.25,"currency":"USD"},{"executeDate":"2026-06-11","recordDate":"2026-06-11","paymentDate":"2026-06-25","value":11,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2,"buy":0.2,"hold":0.6,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.2,"analysts":5,"updateTime":1786593600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AD","date":"2026-09-14","current":6.146202,"percent":0.302583,"low":-273.92211,"twenty":-174.147446,"median":21.178739,"eighty":260.028869,"high":320.844562,"avg":57.119792,"sd":169.650796,"marketCap":3296579480},"quantilePoints":[{"date":"2025-08-15","current":-273.850129,"twenty":-273.893318,"median":-273.850129,"eighty":-273.612593,"marketCap":6572403103},{"date":"2025-08-22","current":-200.933798,"twenty":-273.763753,"median":-273.490226,"eighty":-228.502362,"marketCap":4822411161},{"date":"2025-08-29","current":-194.49692,"twenty":-273.591,"median":-200.933798,"eighty":-194.626488,"marketCap":4667926077},{"date":"2025-09-05","current":-189.890035,"twenty":-273.511821,"median":-195.360711,"eighty":-192.519268,"marketCap":4557360841},{"date":"2025-09-12","current":-184.671298,"twenty":-272.73443,"median":-194.119011,"eighty":-189.199003,"marketCap":4432111159},{"date":"2025-09-19","current":-175.349555,"twenty":-256.070925,"median":-192.368109,"eighty":-183.778715,"marketCap":4208389313},{"date":"2025-09-26","current":-169.950862,"twenty":-200.271577,"median":-189.74607,"eighty":-179.092649,"marketCap":4078820677},{"date":"2025-10-03","current":-180.892213,"twenty":-197.170296,"median":-184.671298,"eighty":-177.638601,"marketCap":4341413113},{"date":"2025-10-10","current":-180.028422,"twenty":-195.252737,"median":-184.059446,"eighty":-177.861746,"marketCap":4320682131},{"date":"2025-10-17","current":-179.200623,"twenty":-194.756057,"median":-183.555568,"eighty":-177.18511,"marketCap":4300814940},{"date":"2025-10-24","current":-177.581015,"twenty":-194.345757,"median":-180.586287,"eighty":-177.242697,"marketCap":4261944349},{"date":"2025-10-31","current":-176.105372,"twenty":-193.617663,"median":-180.892213,"eighty":-177.242697,"marketCap":4226528922},{"date":"2025-11-07","current":-171.642452,"twenty":-192.972746,"median":-180.010426,"eighty":-176.702827,"marketCap":4119418849},{"date":"2025-11-14","current":241.378582,"twenty":-192.09564,"median":-179.920448,"eighty":-175.407141,"marketCap":3917333000},{"date":"2025-11-21","current":240.473745,"twenty":-190.782619,"median":-179.452562,"eighty":-172.916544,"marketCap":3902648400},{"date":"2025-11-28","current":261.764027,"twenty":-189.890035,"median":-179.056658,"eighty":-170.850644,"marketCap":4248168400},{"date":"2025-12-05","current":265.117247,"twenty":-189.602105,"median":-178.588771,"eighty":240.420519,"marketCap":4302587800},{"date":"2025-12-12","current":265.543053,"twenty":-189.098227,"median":-177.958923,"eighty":244.409875,"marketCap":4309498200},{"date":"2025-12-19","current":274.059166,"twenty":-184.671298,"median":-177.329076,"eighty":249.043083,"marketCap":4447706200},{"date":"2025-12-26","current":286.620433,"twenty":-184.613712,"median":-177.149119,"eighty":260.390804,"marketCap":4651563000},{"date":"2026-01-02","current":285.396241,"twenty":-184.556126,"median":-176.681232,"eighty":261.913059,"marketCap":4631695600},{"date":"2026-01-09","current":277.199482,"twenty":-183.965869,"median":-175.78145,"eighty":263.648217,"marketCap":4498670400},{"date":"2026-01-16","current":297.372025,"twenty":-183.569965,"median":-174.161842,"eighty":266.266922,"marketCap":4826050600},{"date":"2026-01-23","current":320.844562,"twenty":-183.555568,"median":-173.981886,"eighty":271.994008,"marketCap":5206986400},{"date":"2026-01-30","current":252.1834,"twenty":-183.238845,"median":-172.02036,"eighty":268.321434,"marketCap":4092684400},{"date":"2026-02-06","current":257.665648,"twenty":-182.648588,"median":-169.950862,"eighty":267.224985,"marketCap":4181655800},{"date":"2026-02-13","current":269.109175,"twenty":-182.115917,"median":238.717297,"eighty":267.224985,"marketCap":4367372800},{"date":"2026-02-20","current":267.938209,"twenty":-181.48247,"median":240.926164,"eighty":268.704659,"marketCap":4348369200},{"date":"2026-02-27","current":255.643071,"twenty":-181.064971,"median":244.409875,"eighty":267.842403,"marketCap":4148831400},{"date":"2026-03-06","current":262.668864,"twenty":-180.769843,"median":247.365175,"eighty":267.342081,"marketCap":4262853000},{"date":"2026-03-13","current":255.643071,"twenty":-180.229973,"median":249.043083,"eighty":266.671437,"marketCap":4148831400},{"date":"2026-03-20","current":82.941723,"twenty":-180.021224,"median":248.376453,"eighty":265.819826,"marketCap":4043906649},{"date":"2026-03-27","current":82.498564,"twenty":-179.985233,"median":245.210832,"eighty":265.628214,"marketCap":4022299967},{"date":"2026-04-02","current":84.413012,"twenty":-179.95644,"median":244.199544,"eighty":265.543053,"marketCap":4115640834},{"date":"2026-04-10","current":87.513828,"twenty":-179.920448,"median":240.447132,"eighty":265.117247,"marketCap":4266824209},{"date":"2026-04-17","current":87.691125,"twenty":-179.920448,"median":236.588268,"eighty":264.265636,"marketCap":4275468504},{"date":"2026-04-24","current":86.627343,"twenty":-179.596527,"median":87.806368,"eighty":264.052733,"marketCap":4223602732},{"date":"2026-05-01","current":88.098909,"twenty":-179.308596,"median":87.655666,"eighty":263.999507,"marketCap":4295350384},{"date":"2026-05-08","current":87.40745,"twenty":-179.200623,"median":87.575882,"eighty":263.414024,"marketCap":4261637632},{"date":"2026-05-15","current":21.135166,"twenty":-178.912692,"median":87.337865,"eighty":263.147896,"marketCap":4402539647},{"date":"2026-05-22","current":21.338509,"twenty":-178.876701,"median":86.919883,"eighty":263.041444,"marketCap":4444896694},{"date":"2026-05-29","current":21.222313,"twenty":-178.646357,"median":86.396857,"eighty":262.74338,"marketCap":4420692667},{"date":"2026-06-05","current":21.55845,"twenty":-178.444805,"median":85.972934,"eighty":262.32822,"marketCap":4490711460},{"date":"2026-06-12","current":16.645033,"twenty":-178.17847,"median":85.475751,"eighty":262.157897,"marketCap":3467226884},{"date":"2026-06-18","current":16.18855,"twenty":-177.926531,"median":85.370237,"eighty":262.136607,"marketCap":3372139635},{"date":"2026-06-26","current":14.893798,"twenty":-177.667394,"median":85.086615,"eighty":261.913059,"marketCap":3102437619},{"date":"2026-07-02","current":15.151088,"twenty":-177.480239,"median":84.907561,"eighty":261.764027,"marketCap":3156032250},{"date":"2026-07-10","current":14.416565,"twenty":-177.285886,"median":83.339562,"eighty":261.593705,"marketCap":3003028221},{"date":"2026-07-17","current":14.495412,"twenty":-177.192309,"median":82.498564,"eighty":261.253061,"marketCap":3019452383},{"date":"2026-07-24","current":14.184174,"twenty":-177.005154,"median":82.259257,"eighty":261.061448,"marketCap":2954620167},{"date":"2026-07-31","current":14.516162,"twenty":-176.767611,"median":81.532476,"eighty":260.944352,"marketCap":3023774530},{"date":"2026-08-07","current":14.794201,"twenty":-176.56606,"median":80.513209,"eighty":260.8379,"marketCap":3081691310},{"date":"2026-08-14","current":5.765224,"twenty":-176.069381,"median":21.824041,"eighty":260.742094,"marketCap":3087300300},{"date":"2026-08-21","current":5.739385,"twenty":-175.867829,"median":21.55845,"eighty":260.635642,"marketCap":3073463660},{"date":"2026-08-28","current":5.731311,"twenty":-175.579899,"median":21.315684,"eighty":260.358869,"marketCap":3069139710},{"date":"2026-09-04","current":6.254541,"twenty":-175.112012,"median":21.259662,"eighty":260.252418,"marketCap":3349331670},{"date":"2026-09-11","current":6.144727,"twenty":-174.161842,"median":21.222313,"eighty":260.167256,"marketCap":3290525950},{"date":"2026-09-14","current":6.156031,"twenty":-174.147446,"median":21.178739,"eighty":260.028869,"marketCap":3296579480}],"updateTime":1789481936987},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AD\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2633176454","title":"Voyager Reports First Quarter 2026 Financial and Operating Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633176454","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633176454?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:01","pubTimestamp":1778184060,"startTime":"0","endTime":"0","summary":"- VY1706 and NBIB-‘233 completed IND-enabling GLP toxicology; clinical entry expected H2 2026 - - Multiple presentations at ASGCT 2026, including late breaker on VY1706 3-month GLP tox data - - Ended ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3290505/36461/en/Voyager-Reports-First-Quarter-2026-Financial-and-Operating-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4130","IND","BK4144","FA","BK4132","BK4590","BK4539","GLP","AD","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633414538","title":"Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633414538","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633414538?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151600,"startTime":"0","endTime":"0","summary":"KOASTAL-2 and -3 studies evaluating navacaprant in major depressive disorder on track for joint topline readout in the second quarter of 2026 Progressing NMRA-511 in Alzheimer’s disease agitation and ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289792/0/en/Neumora-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","NMRA","BK4007","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633145354","title":"Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633145354","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633145354?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:59","pubTimestamp":1778151540,"startTime":"0","endTime":"0","summary":"- Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Exceed Aclaris’ Target Profile, Validating Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing - - Unique Dual ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289773/37216/en/Aclaris-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Provides-Corporate-and-Clinical-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169589451.USD","AD","BK4023","PD","BK4218","PK","IND","ACRS","BK4181","BSA","LU1169590202.USD","BK4132","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633351301","title":"Array Digital Infrastructure Inc  expected to post earnings of $1.14 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633351301","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633351301?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:56","pubTimestamp":1778072166,"startTime":"0","endTime":"0","summary":"Array Digital Infrastructure Inc  expected to post earnings of $1.14 a share - Earnings Preview Array Digital Infrastructure Inc AD.N, AD is expected to  show a fall in quarterly revenue when it repor","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nL8N41J209:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","AD","TDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633133401","title":"BlockchAIn Digital Infrastructure to present at LD Micro Invitational Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2633133401","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633133401?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:33","pubTimestamp":1778070784,"startTime":"0","endTime":"0","summary":"Blockchain Digital Infrastructure to attend LD Micro Invitational Conference in Los Angeles, May 17-19, 2026.Management presentation scheduled for May 19, 2026 at 2:30 p.m. PT.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDLNPSCb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AIB","IE00BN0W2T93.GBP","BK4112","LU0314104364.USD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","SG9999014039.USD","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014005.SGD","SG9999014021.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4585","IE00BKPKM429.USD","TDS","AD","NDAQ","BK4132","BK4588","BK4023","BK4116","LU2210149790.SGD","SG9999014013.SGD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633247559","title":"Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633247559","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633247559?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:15","pubTimestamp":1778012100,"startTime":"0","endTime":"0","summary":"MIAMI, May  05, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-relat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3288288/0/en/Longeveron-to-Report-2026-First-Quarter-Financial-Results-and-Host-Conference-Call-on-May-13-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","MSC","BK4585","BK4181","BK4139","BK4218","LGVN","HST","AD","BK4575","BK4588","BK4150"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633925076","title":"Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633925076","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633925076?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:00","pubTimestamp":1778011200,"startTime":"0","endTime":"0","summary":"NEWTON, Mass., May  05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3288191/0/en/Acumen-Pharmaceuticals-to-Report-First-Quarter-Financial-Results-on-May-12-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","BK4132","BK4539","ABOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632614972","title":"Array Digital Infrastructure to report quarterly results, host webcast conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2632614972","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632614972?lang=en_us&edition=fundamental","pubTime":"2026-05-01 20:18","pubTimestamp":1777637905,"startTime":"0","endTime":"0","summary":"Array Digital Infrastructure will release first-quarter results May 8, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Array Digital Infrastructure Inc. published the original content used to generate this news brief on May 01, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL38wXsy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","BK4132","TDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631634650","title":"INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th","url":"https://stock-news.laohu8.com/highlight/detail?id=2631634650","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631634650?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:00","pubTimestamp":1777550400,"startTime":"0","endTime":"0","summary":"Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, April  30, 2026 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage infl","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3284769/0/en/INmune-Bio-Inc-to-Report-First-Quarter-2026-Financial-Results-and-Provide-Corporate-Update-on-Thursday-May-7th.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","BK4139","AD","INMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631636287","title":"Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2631636287","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631636287?lang=en_us&edition=fundamental","pubTime":"2026-04-30 19:00","pubTimestamp":1777546800,"startTime":"0","endTime":"0","summary":"KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively FDA granted Fast Track designation to K","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3284687/0/en/Kymera-Therapeutics-Announces-First-Quarter-2026-Financial-Results-and-Provides-a-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1162221912.USD","LU0072461881.USD","BK4585","BK4132","BK4006","LU1829250122.USD","AD","BK4161","BK4201","BK4139","KYMR","BPH","EASI","PN","BP","RA","IBD","SID","LU0006061336.USD","LU0320765646.SGD","LU0162691827.USD","BK4588","ATS","BK4096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631529168","title":"Blockchain Digital Infrastructure announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2631529168","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631529168?lang=en_us&edition=fundamental","pubTime":"2026-04-30 04:33","pubTimestamp":1777494784,"startTime":"0","endTime":"0","summary":"Blockchain Digital Infrastructure will hold a virtual annual stockholders meeting via live webcast on June 16, 2026.Shareholders will vote on election of two Class I directors, with Daniel Nelson and Hongfei Zhang nominated.Meeting will also consider ratification of Carr, Riggs & Ingram as independent registered public accounting firm for fiscal years 2025 and 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blockchain Digital Infrastructure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 29, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL4RJvYh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TDS","AIB","BK4023","BK4132","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631525928","title":"Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2631525928","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631525928?lang=en_us&edition=fundamental","pubTime":"2026-04-30 04:05","pubTimestamp":1777493100,"startTime":"0","endTime":"0","summary":"--Independent data monitoring committee (IDMC) determined the trial unlikely to meet primary endpoint – --Alector remains focused on advancing its pipeline of novel ABC-enabled candidates, including a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/29/3284236/0/en/Alector-to-Discontinue-Phase-2-PROGRESS-AD-Trial-of-Nivisnebart-AL101-GSK4527226-in-Early-Alzheimer-s-Disease-Following-Interim-Futility-Analysis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","LU1169589451.USD","LU1169590202.USD","PD","BK4132","IND","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630301145","title":"Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2630301145","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630301145?lang=en_us&edition=fundamental","pubTime":"2026-04-28 20:00","pubTimestamp":1777377600,"startTime":"0","endTime":"0","summary":"Buntanetap improved cognition in pTau217-positive early AD patientsThe drug reduced neurotoxic proteins as well as biomarkers of neuroinflammation and neurodegenerationBuntanetap was safe and well-tol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/28/3282572/0/en/Annovis-Publishes-Phase-2-3-Alzheimer-s-Trial-Results-in-Nature-Portfolio.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS","LU1169589451.USD","LU1169590202.USD","BK4139","PD","AD","BK4132","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143748834","title":"A New \"Dark Horse\" Ingredient Emerges in the Sensitive Skin Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1143748834","media":"Deep News","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143748834?lang=en_us&edition=fundamental","pubTime":"2026-04-27 22:52","pubTimestamp":1777301534,"startTime":"0","endTime":"0","summary":"The Chinese cosmetics industry has seen numerous narratives centered around ingredients over the past few years. From traditional botanical extracts to synthetic biology, a range of \"Chinese...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630276188","title":"Array Digital Infrastructure Inc  expected to post earnings of 86 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2630276188","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630276188?lang=en_us&edition=fundamental","pubTime":"2026-04-25 04:32","pubTimestamp":1777062739,"startTime":"0","endTime":"0","summary":"Array Digital Infrastructure Inc  expected to post earnings of86cents a share - Earnings Preview Array Digital Infrastructure Inc AD.N, AD is expected to  show a fall in quarterly revenue when it repo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nL8N4172JA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","BK4132","TDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629837806","title":"InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=2629837806","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629837806?lang=en_us&edition=fundamental","pubTime":"2026-04-23 21:20","pubTimestamp":1776950400,"startTime":"0","endTime":"0","summary":"BEIJING, April  23, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428) today announced its results and business highlights for the first quarter of 2026 as of 31 March 2026. Over the ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/23/3280053/0/en/InnoCare-Releases-2026-Q1-Results-Strong-Revenue-Growth-and-Sustained-Profitability.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITP","LU0557290698.USD","LU1244550577.SGD","SLE","LU0882574139.USD","LU0795875169.SGD","LU0912757837.SGD","LU2089283258.USD","LU1791710400.SGD","LU1244550494.USD","LU2028103732.USD","LU1732799900.SGD","LU0225283273.USD","LU1989772923.USD","LU0158827781.USD","BK4504","LU0106831901.USD","LU2023251221.USD","LU2133065610.SGD","LU0320765646.SGD","BK4516","LU0106261372.USD","LU0158827948.USD","IBD","BK4127","LU2271345857.HKD","BK4534","LU0971096721.USD","BK4585","LU2357305700.SGD","BK4132","LU0006306889.USD","BK4588","AD","LU0795875086.SGD","LU1074936037.SGD","LU1720051017.SGD","BK4077","LU1732800096.USD","LU2111349929.HKD","IE00BKVL7J92.USD","BK4199","LU0234570918.USD","LU0314104364.USD","LU1162221912.USD","LU2089284900.SGD","LU2347655156.SGD","BK4581","LU0528227936.USD","LU1244550221.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629583294","title":"CMS (867.HK; 8A8.SG): NDA for the Seasonal Allergic Rhinitis Indication of Class 1 Innovative Drug MG-K10 Accepted in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2629583294","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629583294?lang=en_us&edition=fundamental","pubTime":"2026-04-23 20:59","pubTimestamp":1776949140,"startTime":"0","endTime":"0","summary":"SHENZHEN, CHINA, April  23, 2026 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that the New Drug Application (NDA) in China for the Seasonal A","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/23/3279998/0/en/CMS-867-HK-8A8-SG-NDA-for-the-Seasonal-Allergic-Rhinitis-Indication-of-Class-1-Innovative-Drug-MG-K10-Accepted-in-China.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SAR","BK4135","BK4585","LU1894683264.USD","BK4208","BK4588","LU2500361329.USD","LU0545039389.USD","LU1894683348.USD","IE0031619046.USD","LU2346227817.USD","BK4132","LU1003077747.HKD","IE00B19Z4B17.USD","MG","BK4123","LU2637428348.USD","LU0738911758.USD","LU0949170772.SGD","IE00B66KJ199.SGD","LU0553294199.USD","LU0661504455.SGD","IE00B7SZL793.SGD","AD","CMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629010016","title":"Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”","url":"https://stock-news.laohu8.com/highlight/detail?id=2629010016","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629010016?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:00","pubTimestamp":1776855600,"startTime":"0","endTime":"0","summary":"License of the MIT patent strengthens Rafael’s intellectual property around cyclodextrins as an Active Pharmaceutical Ingredient (API) in the treatment of ApoE4-positive Alzheimer’s DiseaseNEWARK, N.J","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/22/3278798/0/en/Rafael-Holdings-Announces-Patent-Licensing-Agreement-with-MIT-for-Small-Molecules-to-Improve-Myelination-in-ApoE4-positive-Alzheimer-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","MIT","BK4233","BK4503","BK4535","CNS","BK4551","RFL","BK4023","BK4007","API","BK4135","BK4205","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629743778","title":"Did Proposed Officer Liability Shield Just Shift Array Digital Infrastructure's (AD) Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2629743778","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629743778?lang=en_us&edition=fundamental","pubTime":"2026-04-21 01:04","pubTimestamp":1776704670,"startTime":"0","endTime":"0","summary":"Array Digital Infrastructure, Inc. has proposed amending its Restated Certificate of Incorporation to add exculpation protections for certain corporate officers against monetary damages for breaches of the fiduciary duty of care, subject to limitations, with shareholders asked to vote on the change at the May 19, 2026 annual meeting.\nThis move, which would extend protections similar to those already available to directors, raises important questions about how investors assess management...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9031000-choice1-main-header/1585186715767","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9031000-choice1-main-header/1585186715767"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/telecom/nyse-ad/array-digital-infrastructure/news/did-proposed-officer-liability-shield-just-shift-array-digit","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/telecom/nyse-ad/array-digital-infrastructure/news/did-proposed-officer-liability-shield-just-shift-array-digit","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4132","AD","DTCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626159983","title":"Lynk Pharmaceuticals Announces NDA Acceptance for Zemprocitinib by NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2626159983","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626159983?lang=en_us&edition=fundamental","pubTime":"2026-04-10 08:00","pubTimestamp":1775779200,"startTime":"0","endTime":"0","summary":"SHANGHAI, HANGZHOU, China and BOSTON, April 10, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. , a clinical-stage innovative drug development company focused on therapies for immune and inflammatory diseases, today announced that the New Drug Application  for its core product, zemprocitinib capsules, for the treatment of moderate-to-severe atopic dermatitis , has been formally accepted by the Center for Drug Evaluation  of the China National Medical Products Administration . This acceptance marks a critical milestone in the company's clinical development in inflammatory skin diseases and represents an important step toward Lynk Pharmaceuticals' transition to commercialization. Zemprocitinib capsules have the potential to provide a new treatment option for patients with atopic dermatitis.Preclinical and clinical studies have demonstrated that zemprocitinib potently and dose-dependently inhibits multiple JAK1-mediated inflammatory signaling pathways, supporting its therapeutic poten","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/lynk-pharmaceuticals-announces-nda-acceptance-for-zemprocitinib-by-nmpa-302738518.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4017","RA","CDE.AU","AS","LU1223082196.USD","BK7050","CDE","LU1223083913.SGD","BK4132","LU1223082519.USD","BK4202","BK4099","AD","ZK"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":190,"code":"91000000","status":"200"}]}}